The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials
Although it is not covered by insurance plans the out-of-pocket cost is reasonable
During a follow-up of 7.8 years, this intervention reduced the risk of microvascular and macrovascular complications by more than 50% and decreased all-cause mortality by 46% [1, 2]
they work opposite of each other so that blood sugar decreases during and right after meals (thanks to insulin), and levels increase between meals, giving the body steady energy levels (due to glucagon)
Real World Impact: Current Use and Outcomes These medications are no longer niche, they're influencing population level trends: Rapid Growth in Use In the U.S., reported use of GLP-1 weight loss drugs has more than doubled in the past year, from about 5.8% of adults in early 2024 to over 12% in 2025 Women tend to use these medications at higher rates than men, with 15.2% vs
